This morning healthcare giant Ansell Limited (ASX: AMP) reported its profit result for the six-month period ending June 30, 2017. Below is a summary of the result, with comparisons to relevant prior corresponding periods and all numbers in US dollars.
- Earnings before interest and tax from continuing businesses of $177.8 million
- Total sales from continuing businesses of $1,375 million
- Earnings per share from continuing businesses of 81 cents
- Earnings per share from discontinued operations 19 cents
- Total dividends of 44 cents per share, 43.5 cps in prior year
- To sell its Sexual Wellness condoms business for $600 million
- Expects to continue share buyback from proceeds of Sexual Wellness sale
This is another typically solid result from one of the leading healthcare businesses among the S&P/ASX 200 (Index: ^AJXO) (ASX: XJO) index of leading companies.
The result though missed analysts’ expectations and the Ansell share price has fallen 3.7 per cent to $20.80 this morning as the flat growth and currency headwinds took their toll on investors’ expectations.
The group posted 6 per cent organic sales growth over the six-month period ending June 30 2017 and its medical gloves and protective wear businesses continues to enjoy market-leading status and large global addressable markets.
The company’s decision to sell its consumer-facing condoms business for $600 million mean its management team has a test ahead in redeploying the capital at a good return for both the business and shareholders. Acquisitions and share buybacks remain on the agenda as the group attempts to grow its core business-to-business protective wear operations.
Changing hands for $20.80 the stock trades on 20x FX-adjusted earnings from continuing operations with a trailing FX-adjusted dividend yield in the region of 2.7 per cent. Alongside the likes of Cochlear Limited (ASX: CSL), Ansell remains one of the better healthcare businesses on the local market.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
Motley Fool contributor Tom Richardson owns shares of Cochlear Ltd.
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- On a serendipitous day, Tom Richardson is leaving the building – December 17, 2019 11:55am
- Why Aerometrex shares have doubled their IPO price – December 16, 2019 4:32pm
- Why the National Veterinary Care share price is going nuts today – December 16, 2019 3:39pm